Press release

March 22ⁿᵈ, 2022

Clinical validation of NAVOY® Sepsis in intensive care presented at the 41ˢᵗ International Symposium on Intensive Care & Emergency Medicine

AlgoDx today announced that results of the clinical validation trial *Early prediction of sepsis in hospitalized patients using a machine learning algorithm, a randomized clinical validation trial* are presented at the ISICEM congress in Brussels. The aim of the study, which was led by Dr Fredrik Sjövall MD, PhD, DEAA, EDIC, was to validate the prognostic accuracy of NAVOY® Sepsis at predicting sepsis three hours in advance in intensive care patients.

304 intensive care patients were monitored during their ICU stay using NAVOY® Sepsis, of which 44 patients had been diagnosed with Covid-19. The study (NCT04570618) is the largest randomized clinical trial with a machine learning sepsis predictor ever conducted, and the first study that clinically validates a sepsis predictor against the Sepsis-3 criteria.

The primary objective results concluded that the accuracy, sensitivity, and specificity met the criteria for a successful primary analysis, as specified in the Clinical Study Protocol.

The results are presented by Dr Sjövall as late-breaking abstract P064 during the virtual poster presentation at the 41st International Symposium on Intensive Care & Emergency Medicine in Brussels, March 22-25, 2022.

About NAVOY® Sepsis
NAVOY® Sepsis is a machine learning algorithm that uses routinely collected ICU data to accurately predict sepsis onset in ICU patients three hours earlier than today's state-of-the-art (SEPSIS 3 protocol). NAVOY® Sepsis has obtained the relevant regulatory clearances for the EU, UK and US markets. Further information can be found in the following reference: Persson et al. A Machine Learning Sepsis Prediction Algorithm for Intended Intensive Care Unit Use (NAVOY® Sepsis): Proof-of-Concept Study. JMIR Form Res 2021;5(9):e28000, DOI: 10.2196/28000.

About AlgoDx
AlgoDx is a Swedish clinical stage a privately-owned medical software company associated with Uppsala University.

AlgoDx AB, Götgatan 22A, Stockholm, Sweden, algodx.com

Press contact: David Becedas, CEO AlgoDx. Tel: +46 72 232 83 48.
david.becedas@algodx.com